CSL Limited (OTCMKTS:CSLLY – Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 12,600 shares, an increase of 4,100.0% from the March 15th total of 300 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 201,200 shares, the short-interest ratio is presently 0.1 days.
CSL Stock Up 1.8 %
CSLLY opened at $77.94 on Wednesday. The company has a 50 day moving average of $79.72 and a two-hundred day moving average of $87.29. CSL has a 52-week low of $70.22 and a 52-week high of $109.00. The company has a current ratio of 2.18, a quick ratio of 0.97 and a debt-to-equity ratio of 0.58.
Analyst Ratings Changes
Separately, The Goldman Sachs Group raised CSL to a “strong-buy” rating in a research note on Thursday, January 16th.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Articles
- Five stocks we like better than CSL
- Most active stocks: Dollar volume vs share volume
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- How to Invest in the FAANG Stocks
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Congress! Who Traded What During the Tariff-Induced MeltdownÂ
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
